


Stabilis



Sodium Phosphate



Noms commerciaux

phosphate monopotassique France
Renaudin



Stabilité des solutions

PVC		0,030 mmol/ml	23°C		63			3945
PVC		0,030 mmol/ml	4°C		63			3945
PVC		0,150 mmol/ml	23°C		63			3945
PVC		0,150 mmol/ml	4°C		63			3945



















































Stabilité en mélange

?		0,01 mmol/ml	25°C	?	Ampicillin sodium : 12 mg/ml	48		3880



Compatibilités

Sodium Phosphate : 0,12 mmol/ml Amiodarone hydrochloride : 6 mg/ml		1611
Sodium Phosphate : 3 mmol/ml Caffeine : 10 mg/ml		3964
Sodium Phosphate Calcium gluconate		3644
Sodium Phosphate : 3 mmol/ml Calcium gluconate : 100 mg/ml		789
Sodium Phosphate : 0,5 mmol/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
Sodium Phosphate : 0,5 mmol/ml Ceftaroline fosamil : 2,22 mg/ml		3249

		Sodium Phosphate : 0,5 mmol/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Sodium Phosphate : 0.5 mmol/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Sodium Phosphate Ceftobiprole medocaril sodium		4650
		Sodium Phosphate : 0.5 mmol/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Sodium Phosphate : 0.5 mmol/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Sodium Phosphate : 0,3 mmol/ml Ciprofloxacin lactate : 2 mg/ml		268
		Sodium Phosphate : 0.5 mmol/ml Doripenem : 5 mg/ml		2262
		Sodium Phosphate : 0.5 mmol/ml Fosfomycin : 30 mg/ml		4055
		Sodium Phosphate 0.5 mmol/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Sodium Phosphate : 3 mmol/ml		1415
		Sodium Phosphate : 3 mmol/ml Ciprofloxacin lactate : 2 mg/ml		261
		Sodium Phosphate : 3 mmol/ml Lansoprazole : 0,55 mg/ml		1625
		Sodium Phosphate : 3 mmol/ml Magnesium sulfate : 500 mg/ml		4389
		Sodium Phosphate Magnesium sulfate		3838
		Sodium Phosphate : 3 mmol/ml Meropenem : 50 mg/ml		4319
		Sodium Phosphate : 0.5 mmol/ml Micafungin : 1.5 mg/ml		2108
		Sodium Phosphate : 0.5 mmol/ml Plazomicin sulfate : 24 mg/ml		4145
		Sodium Phosphate : 0,3 mmol/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Sodium Phosphate : 0.5 mmol/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Sodium Phosphate : 0.5 mmol/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Sodium Phosphate : 0.5 mmol/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Sodium Phosphate : 1 mmol/ml		301



Voie d'administration





Bibliographie

	Type	Source
261	Revue	Percy LA, Rho JP. Visual compatibility of ciprofloxacin with selected components of total parenteral nutrient solutions during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 715-716.
268	Revue	Benjamin BE. Ciprofloxacin and sodium phosphate not compatible during actual Y-site injection. Am J Health-Syst Pharm 1996 ; 53: 1850-1851.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
789	Revue	Garner SS, Wiest DB. Compatibility of drugs separated by a fluid barrier in a retrograde intravenous infusion system. Am J Hosp Pharm 1990 ; 47: 604-606.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaryl with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015

3838	Laboratoire	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3880	Revue	Maher M, Jensen Kara J, Lee David, Nix David E Stability of Ampicillin in Normal Saline and Buffered Normal Saline. Int J Pharm Compound 2016 ; 20, 4 : 338-342
3945	Revue	Perks W, Iazzetta J, Chan P.C, Brouzas A, Law S, Walker S.E. Extended Stability of Sodium Phosphate Solutions in Polyvinyl Chloride Bags. Can J Hosp Pharm 2017 ; 70,1 : 7-12.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionnaire

 électrolyte	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Polyvinyl chlorure
 NaCl 0,9% ou glucose 5%	 Lumière
 Jour	 Stabilité en mélange
 Solvant	 Molécule
 Non précisé	 Chlorure de sodium 0,9%
 Non précisée	 Heure
 Compatibilités	 Précipitation immédiate
 Incompatible	 Glucose 5%
 Précipitation en 4 heures	 Aucun
 Incompatibilité non précisée	 Compatible
 Turbidité immédiate	RL Ringer lactate
 Précipitation en 1 heure	 Chlorure de sodium 0,45%
 Turbidité en 1 heure	 Instabilité de l'émulsion immédiate
 Nutrition parentérale (mélange ternaire)	 Dégagement gazeux
 Eau pour préparation injectable	 Nutrition parentérale (mélange binaire)
 Voie d'administration	 Perfusion intraveineuse
 Perfusion continue	 Bibliographie
 Dictionnaire	